Cav3.1 is a neuronal leucine sensor that mediates satiety and weight loss in response to dietary protein
Tsang AH, Heeley N, Alcaino C, Hwang E, Lam BY, Rahman T
Cell Metabolism (2026)
Cambridge Institute of Metabolic Science group identifies Cav3.1 — a T-type voltage-gated calcium channel — as the hypothalamic POMC-neuron leucine sensor that mediates protein-induced satiety, and shows pharmacological Cav3.1 activation in the mediobasal hypothalamus drives weight loss in obese mice and potentiates liraglutide's anorectic response.
This Cell Metabolism paper from Clémence Blouet's group at the Cambridge Institute of Metabolic Science (IMS-MRL) identifies a previously unknown molecular component of the hypothalamic protein-satiety circuit and shows it potentiates the appetite-suppressive effect of liraglutide. The work answers a long-standing question in nutritional neuroscience — how do appetite-regulating neurons in the hypothalamus actually sense dietary protein?
The authors find that Cacna1g, the gene encoding the T-type voltage-gated calcium channel Cav3.1, is enriched in hypothalamic leucine-sensing neurons and is required for neuronal leucine sensing. Pharmacological inhibition of Cav3.1 blunts leucine-induced activation of pro-opiomelanocortin (POMC) neurons in cultured neurons and acute brain slices, and suppresses the anorectic response to hypothalamic leucine in vivo. Genetic deletion of Cacna1g specifically in POMC neurons abolishes the appetite- and weight-suppressive effects of high-protein feeding in mice.
Mechanistically, leucine binds a hydrophobic pocket of Cav3.1 and lowers its threshold for voltage-dependent activation — a direct ligand-channel interaction rather than an indirect intracellular signalling cascade. Pharmacological activation of mediobasal hypothalamic Cav3.1 promotes weight loss in diet-induced obese mice and — critically for the peptide-therapeutics field — potentiates the responses to anorectic agents, including liraglutide.
The findings nominate Cav3.1 as a tractable molecular target for anti-obesity therapy and a potential combination partner for GLP-1 receptor agonists.
The study is conducted in mice, with primary readouts in cultured neurons, brain slices, and DIO (diet-induced obese) mouse models. Translation to human obesity treatment is several rigorous steps away, including small-molecule selectivity (Cav3.1 has paralogues Cav3.2 and Cav3.3 with distinct tissue distributions including cardiac tissue, where T-type channel modulation has historically created drug-development concerns) and brain penetrance of any future drug candidate.
The liraglutide-potentiation finding is from pharmacological mediobasal-hypothalamic Cav3.1 activation; the abstract does not state whether the same potentiation is observed with chronic dietary high-protein feeding, or whether a clinically tractable oral Cav3.1 modulator has been identified. The translational claim — that Cav3.1 modulation could augment GLP-1RA efficacy in humans — is hypothesis-generating, not validated.
Mouse-to-human translation of POMC-neuron circuitry is non-trivial; the species-specific differences in melanocortin signalling and leucine pharmacokinetics are well-documented.
The Cell Metabolism reviewers and Cambridge group are extremely credible, and the multi-method convergence (cultured neurons, brain slices, in-vivo behaviour, POMC-conditional knockout, structural-binding inference, in-vivo pharmacology) is the standard of evidence the journal demands.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.